Twitter Feed: The Lancet Haematology
The effect of granulocyte-colony stimulating factor, decitabine, and busulfan–cyclophosphamide versus busulfan–cyclophosphamide conditioning on relapse in patients with myelodysplastic syndrome or secondary acute myeloid leukaemia evolving from myelodysplastic syndrome undergoing allogeneic… - 1 day
Our results suggest that G-CSF, decitabine, and busulfan–cyclophosphamide conditioning is a better choice than busulfan–cyclophosphamide conditioning for patients with myelodysplastic syndrome-RAEB or secondary acute...
-
Now OF: G-CSF and decitabine plus busulfan–cyclophosphamide conditioning reduced 2-year cumulative incidence of relapse versus busulfan–cyclophosphamide in patients with MDS-RAEB or AML secondary to MDS receiving alloHSCT in a ph 3 trial. #leusm #mdsm https://t.co/AKe3FfHbTQ https://t.co/AKe3FfHbTQ - view on twitter
Assisted reproductive technologies (ART) are not yet systematically available to people with sickle cell disease or their parents. Fertility care for these groups requires...
-
Now OF: In their Viewpoint, Lydia H Pecker and colleagues contend that fertility care should be incorporated into the comprehensive care model for patients with #SickleCell disease. https://t.co/5roHaj4uV8 - view on twitter
More coverage:
#sicklecell
Myelodysplastic syndrome refers to a group of blood disorders characterised by clonal expansion of mutated blood cells, which can progress into secondary acute myeloid...
"Given that the patient sample size was small, the results ... especially those suggesting that the treatment can overcome the adverse prognosis of RUNX1 and TP53 mutations, will need to be validated in large sample studies." Comment by Xi Zhang. https://t.co/YN6tFecxIk - view on twitter